早期乳腺癌区域淋巴结局部处理

doi:10.16139/j.1007-9610.2022.05.006

外科理论与实践 ›› 2022, Vol. 27 ›› Issue (05): 406-410.doi: 10.16139/j.1007-9610.2022.05.006

早期乳腺癌区域淋巴结局部处理

曹璐, 郑思悦, 陈佳艺()

上海交通大学医学院附属瑞金医院放射治疗科，上海 200025

收稿日期:2022-07-28 出版日期:2022-09-25 发布日期:2022-11-10
通讯作者: 陈佳艺 E-mail:chenjiayi0188@aliyun.com
基金资助:
国家重点研发计划(2016YFC0105409);上海申康医院发展中心临床三年行动计划(SHDC2020CR2052B);上海市科学技术委员会“科技创新行动计划”(19411950900);上海市科学技术委员会“科技创新行动计划”(19411950901)

Management of regional lymph nodes in early-stage breast cancer

CAO Lu, ZHENG Siyue, CHEN Jiayi()

Received:2022-07-28 Online:2022-09-25 Published:2022-11-10
Contact: CHEN Jiayi E-mail:chenjiayi0188@aliyun.com

摘要/Abstract

关键词: 早期乳腺癌, 腋窝手术, 区域淋巴结放疗, 个体化放疗

中图分类号:

R737.9

曹璐, 郑思悦, 陈佳艺. 早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410.

CAO Lu, ZHENG Siyue, CHEN Jiayi. Management of regional lymph nodes in early-stage breast cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.

参考文献 29

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2]	Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer[J]. N Engl J Med, 2015, 373(4):307-316.
[3]	Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage Ⅰ-Ⅲ breast cancer(EORTC 22922/10925):15-year results of a randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(12):1602-1610.
[4]	Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer[J]. J Clin Oncol, 2016, 34(4):314-320.
[5]	Kim YB, Byun HK, Kim DY, et al. Effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial[J]. JAMA Oncol, 2022, 8(1):96-105.
[6]	Balic M, Thomssen C, Würstlein R, et al. St.Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment[J]. Breast Care, 2019, 14(2):103-110.
[7]	Zhang L, Zhou M, Liu Y, et al. Is it beneficial for patients with pT1-2N1M0 breast cancer to receive postmastectomy radiotherapy? an analysis based on RecurIndex assay[J]. Inter J Cancer, 2021, 149(10):1801-1808.
[8]	Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10):927-933.
[9]	Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs. no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017, 318(10):918-926.
[10]	NCCN clinical practice guidelines in oncology-breast cancer(Version 1.2012)[DB/OL]. [2022-07-28].
[11]	Galimberti V, Cole Bf, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases(IBCSG 23-01):10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385-1393.
[12]	Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000[J]. Ann Surg Oncol, 2013, 20(1):120-127.
[13]	Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12):1303-1310.
[14]	Sávolt á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase Ⅲ, non-inferiority trial[J]. Eur J Surg Oncol, 2017, 43(4):672-679.
[15]	Wang NN, Yang ZJ, Wang X, et al. A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective ana-lysis and nomogram development[J]. Breast Cancer, 2018, 25(6):629-638.
[16]	Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial[J]. J Clin Oncol, 2014, 32(32):3600-3606.
[17]	Goyal A, Mann GB, Fallowfield L, et al. POSNOC—PO-sitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in wo-men with early-stage breast cancer who have metastases in one or two sentinel nodes[J]. BMJ Open, 2021, 11(12):e054365.
[18]	Gentilini O, Botteri E, Leonardi MC, et al. Ipsilateral axillary recurrence after breast conservative surgery: the protective effect of whole breast radiotherapy[J]. Radiother Oncol, 2017, 122(1):37-44.
[19]	Turashvili G, Wen HY. Multigene testing in breast cancer: what have we learned from the 21-gene recurrence score assay?[J]. Breast J, 2020, 26(6):1199-1207.
[20]	Reimer T, Stachs A, Nekljudova V, et al. Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c/iT1-2) in the context of breast conserving therapy: first results follow-ing commencement of the intergroup-sentinel-mamma (INSEMA) trial[J]. Geburtshilfe Frauenheilkd, 2017, 77(2):149-157.
[21]	Garda AE, Hunzeker AE, Michel AK, et al. Intensity modulated proton therapy for bilateral breast or chest wall and comprehensive nodal irradiation for synchronous bilateral breast cancer: initial clinical experience and dosimetric comparison[J]. Adv Radiat Oncol, 2022, 7(3):100901.
[22]	Jacobson G, Bunda-Randall N, Wen S, et al. Axillary lymph node coverage with 3-dimensional tangential field irradiation and correlation with heart and lung dose[J]. Adv Radiat Oncol, 2017, 2(4):630-635.
[23]	Ahrouch I, van Gestel D, Koshariuk O, et al. Unintended dose to the lower axilla in adjuvant radiotherapy for breast cancer: differences between tangential beam and VMAT[J]. Radiother Oncol, 2021, 164:282-288.
[24]	Hildebrandt G, Stachs A, Gerber B, et al. Central review of radiation therapy planning among patients with breast-conserving surgery: results from a quality assurance process integrated into the INSEMA trial[J]. Int J Radiat Oncol Biol Phys, 2020, 107(4):683-693.
[25]	Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-Ⅲ trial[J]. Trials, 2018, 19(1):667.
[26]	Weber WP, Matrai Z, Hayoz S, et al. Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)[J]. Breast, 2021, 60:98-110.
[27]	Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7):609-618.
[28]	Boughey JC. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071(Alliance) clinical trial[J]. JAMA, 2013, 310(14):1455-1461.
[29]	Gandhi A, Coles C, Makris A, et al. Axillary surgery following neoadjuvant chemotherapy-multidisciplinary guidance from the association of breast surgery, faculty of clinical oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology[J]. Clin Oncol, 2019, 31(9):664-668.

早期乳腺癌区域淋巴结局部处理

Management of regional lymph nodes in early-stage breast cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 7

编辑推荐

Metrics

本文评价

[1]	姚成才　陈明　刘长春　黄传蔷　冼家仪　严国标　陈庞洲. 硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-.
[2]	于芷晗，王亮亮，赵雪峰. 动态增强核磁共振在早期乳腺癌保乳手术中的应用研究[J]. 组织工程与重建外科杂志, 2018, 14(6): 323-326.
[3]	陈佳艺,. 早期乳腺癌的术中放疗[J]. 外科理论与实践, 2014, 19(05): 380-384.
[4]	洪进, 陈小松, 毛艳, 李亚芬,. Luminal A型早期乳腺癌化疗决策的影响因素分析[J]. 外科理论与实践, 2014, 19(05): 407-411.
[5]	张俊. 国外医学文献摘要[J]. 外科理论与实践, 2004, 9(02): 98-.
[6]	张斌. 就早期乳腺癌保乳手术治疗的若干认识[J]. 外科理论与实践, 2001, 6(04): 197-198.
[7]	张斌,何文贵,蔡玉娥,张齐,英子伟,蒋书玲. 保守性手术加放疗治疗早期乳腺癌的10年疗效[J]. 外科理论与实践, 2001, 6(04): 216-218.